Granules India Limited has announced that its Unit V facility, located in Anakapally, Visakhapatnam, Andhra Pradesh, has been awarded the European Union Good Manufacturing Practice (EU GMP) certificate. This certification marks a significant milestone in the company’s compliance with international pharmaceutical manufacturing standards.
The certification was granted following an audit conducted in November 2024 by the National Centre for Public Health and Pharmacy, Hungary. The EU GMP certification is a crucial regulatory requirement for exporting pharmaceutical products to European markets, ensuring that the facility meets stringent quality and safety standards.
The Unit V facility plays a key role in the company’s manufacturing capabilities, focusing on the production of both Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs). The facility is involved in manufacturing formulations for oncology and non-oncology products, broadening the company’s product portfolio in critical therapeutic areas.
Securing an EU GMP certificate enhances Granules India’s ability to supply pharmaceutical products to European markets, demonstrating its commitment to global regulatory compliance. This certification may help the company strengthen its presence in regulated markets and explore new business opportunities in the EU pharmaceutical sector.
Granules India stated in a regulatory filing that its consolidated profit after tax decreased by 6% year-on-year to ₹118 crore for the third quarter ended 31 December 2024.
The company had reported a profit after tax of ₹126 crore during the October-December quarter of the previous financial year.
Revenue from operations declined to ₹1,138 crore in the third quarter, compared to ₹1,156 crore in the corresponding period last year.
On January 30, 2025, at 9:39 AM, Granules India shares traded at ₹554.15 per share on the NSE.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jan 30, 2025, 2:44 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates